Towards disease modification in osteoarthritis

Francesco Dell'Accio, Cosimo De Bari

Research output: Contribution to journalComment/debatepeer-review


In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.
Original languageEnglish
JournalOsteoarthritis and Cartilage
Publication statusE-pub ahead of print - 15 May 2023


Dive into the research topics of 'Towards disease modification in osteoarthritis'. Together they form a unique fingerprint.

Cite this